osimertinib: 29 Real Stories

29 stories match osimertinib. 11 of them mention surgery.

  1. T790M-negative lung cancer on afatinib after AZD9291 trial ineligibility

    Advance Care Planning · afatinib

    This Noxte entry followed a disappointing oncology update on 19 April. The patient learned that the blood sample sent to the laboratory was negative for T790M resistance, so he could not enter the AZD9291/osimertinib clinical trial. He found that frustrating…

    Read this story
  2. Lung cancer on afatinib after liquid biopsy showed T790M resistance no longer detected

    afatinib · erlotinib

    This Noxte post explained how liquid biopsy was beginning to affect the patient’s lung cancer care. He had been participating in blood-based monitoring to track treatment effects and possible resistance. At an oncology visit, his doctors had the latest blood…

    Read this story
  3. Lung cancer with acquired T790M resistance: erlotinib switched to afatinib while AZD9291/TAGRISSO trial was considered

    Metastatic · T790M Resistance Positive · afatinib · Diagnostic Workup

    By January 2016, this Spanish lung cancer blogger was marking 2 years of survival while facing a new treatment setback. Recent bronchoscopy and blood testing confirmed that the cancer had developed resistance, including the T790M mutation. That finding…

    Read this story
  4. Lung cancer progression on Tarceva with urgent T790M resistance testing planned

    Metastatic · Diagnostic Workup · erlotinib

    In January 2016, this lung cancer patient learned that a recent CT scan explained his worsening cough. The scan showed clear progression: the right upper-lobe mass had grown to about 4.9 x 5 cm, with extension to the visceral pleura, involvement around the…

    Read this story
  5. EGFR-mutated NSCLC on Tarceva with CT follow-up pending and future resistance options discussed

    EGFR Mutation · erlotinib · Imaging Diagnostics

    In December 2015, this patient was living with EGFR-mutated non-small cell lung cancer and taking Tarceva, also called erlotinib, which he had started in January. Much of this post reflected his effort to understand the fast-changing treatment landscape. He…

    Read this story